Abiopharma

🔍 Yi Steven (Director)

Company: MediaAlpha, Inc. (MAX)

Report Date: 2026-03-15

Detailed Transactions and Holdings:

• Acquired 448,500 shares of Class A Common Stock (Direct)
  Date: 2026-03-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,068,474.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,000 shares of Class A Common Stock at $9.9318 per share (Direct)
  Date: 2026-03-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,064,474.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 5,227 shares of Class A Common Stock at $9.9401 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,059,247.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Acquired 149,550 shares of Performance Restricted Stock Units (2026 PRSUs) (Derivative)
  Date: 2026-03-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 149,550.00 | transaction_form_type: 4 | Footnotes: F5, F6, F6

Footnotes:

• F1: Consists of restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. One sixteenth of the RSUs will vest on May 15, 2026 and the remainder will vest quarterly over the following four years, in each case subject to continued employment with the Issuer through each vesting date.
• F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person primarily to cover taxes resulting from the vesting of RSUs.
• F3: Reflects the weighted-average sale price for shares sold in multiple transactions at prices ranging from $9.84 to $9.99 per share. The Reporting Person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
• F4: Reflects the weighted-average sale price for shares sold in multiple transactions at prices ranging from $9.63 to $10.04 per share. The Reporting Person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
• F5: Represents Performance Based Restricted Stock Units (PRSUs) granted to the Reporting Person on March 15, 2026, pursuant to the Issuer's Omnibus Equity Incentive Plan. Each PRSU represents a contingent right to receive shares of Issuer's Class A Common Stock.
• F6: The PRSUs will be earned subject to achievement of Adjusted EBITDA goals for fiscal 2026, fiscal 2027, and fiscal 2028, with each fiscal year measured separately for purposes of determining PRSU vesting. One-third of the PRSU grants are tied to Adjusted EBITDA performance against pre-established threshold, target, and maximum Adjusted EBITDA goals for each fiscal year, corresponding to vesting of 50%, 100% and 200% of the target shares, respectively. Following the completion of each performance period, any earned PRSUs for that performance period will remain subject to continued service-based vesting through the end of the three-year period."
• F7: If PRSUs become eligible to vest after approval from the Compensation Committee of the Board of Directors of the Issuer on the achievement of the performance measures, the eligible units will settle on March 15, 2029.